Authors
Latest:
Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple MyelomaSuzanne Trudel, MSc, MD, discusses the implications of results from the DREAMM-7 and DREAMM-8 trials in relapsed/refractory multiple myeloma.
Latest:
Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal DiseasePeter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.
Latest:
New California Tobacco Cessation Policy Research Center to be Housed at Cancer CenterUC Davis Comprehensive Cancer Center has launched the state’s first-ever Tobacco Cessation Policy Research Center.
Latest:
Dr Cohen on Teclistamab Plus Talquetamab in R/R Multiple MyelomaYael Cohen, MD, discusses primary efficacy findings from the phase 1/2 RedirecTT-1 trial, which is investigating the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
Latest:
Dr Oswalt on the Effects of Palliative Care Timing on End-of-Life Care in mNSCLCCameron James Oswalt MD, discusses a study evaluating the timing of palliative care referral and its effect on end-of-life care outcomes in mNSCLC.
Latest:
Highlighting the Efficacy of VaxEffect With Immune Response to COVID-19 VaccinesRenold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.
Latest:
Exploring Real-World Evidence Presented at ATA 2023Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.
Latest:
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCLHayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.
Latest:
Dr. VanderWalde on the Importance of Multidisciplinary Care in Rectal CancerNoam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.
Latest:
Dr Lee on Tremelimumab Plus Durvalumab in Ovarian CancerJung-Yun Lee, MD, PhD, discusses primary efficacy and safety findings from the phase 2 KGOG3046/TRU-D trial in patients with newly diagnosed ovarian cancer.
Latest:
Missing a Rare Cause of Hereditary CancerNew research from Cedars-Sinai Cancer investigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common cause of hereditary colorectal and endometrial cancers.
Latest:
Nerlakanti on the Role of HDAC Inhibitors in OsteosarcomaNiveditha Nerlakanti, discusses the investigation of HDAC inhibitors in osteosarcoma.
Latest:
Charting a Path for the Integration of Immunotherapy in the Treatment of Multiple MyelomaFenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.
Latest:
Dr Merryman on the Evolution of MRD Assays in LymphomaReid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.
Latest:
Dr. Mouhieddine on Outcomes After Bispecific Antibodies in R/R Multiple MyelomaTarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.
Latest:
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular CarcinomaWilliam Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.
Latest:
Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLCMark Awad, MD, PhD, discusses the significance of the FDA approval of perioperative nivolumab for patients with resectable NSCLC.
Latest:
Dr Stewart on the Multiomic Landscape of Squamous Cell Lung CancerPaul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.
Latest:
Dr. Singh on the Continued Investigation of Enfortumab Vedotin/Pembrolizumab in Urothelial CancerVikas Kumar Singh, MD, discusses the potential benefit of the combination of enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.
Latest:
Dr Ackroyd on the Assessment of Time Toxicity in Advanced/Recurrent Endometrial CancerSarah Ackroyd, MD, MPH, discusses the rationale and key results from a study of time-related treatment burden in patients receiving treatment for advanced, recurrent endometrial cancer.
Latest:
Future of MFExperts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.
Latest:
Dr. Sia on a Novel Classification System in Intrahepatic CholangiocarcinomaDaniela Sia, PhD, discusses a novel microenvironment-based classification system of intrahepatic cholangiocarcinoma.
Latest:
Dr. Shah on Trials Examining Cilta-Cel in Relapsed/Refractory Multiple MyelomaMansi R. Shah, MD, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.
Latest:
Dr. Hurvitz on Sequencing Therapeutic Options in HER2+ Breast CancerSara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer.
Latest:
Dr. Lee on the Importance of Collaboration in Precision MedicineKelvin P. Lee, MD, discusses the importance of collaboration in precision medicine.
Latest:
Dr. Strickland on the Diagnosis of ESCCStephen A. Strickland, MD, MSCI, discusses a step-by-step approach for the diagnosis and workup of esophageal squamous cell carcinoma.
Latest:
Practical Advice on the Use of ctDNA Testing in Breast CancerClosing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.
Latest:
Dr. Li on the Interim Results of a Phase 1 Trial With Surufatinib in NETsDaneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.
